Comparison outcomes of a large cohort of moderate and severe COVID-19 patients received remdesivir alone with patients who received remdesivir in combination with lopinavir/ ritonavir in addition to standard management.
Aim of the study 1. To assess the difference in patients' clinical status improvement between patients receiving remdesivir alone and patients receiving remdesivir and lopinavir/ ritonavir. 2. To detect time to improvement in oxygenation among both groups. 3. To detect duration of hospitalization and mortality rate in both groups. 4. To detect incidence and duration of mechanical ventilation in both treatment arms. 5. To monitor of adverse events of both drugs.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
90
Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily.
Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days
Beni-suef University
Banī Suwayf, Egypt
RECRUITINGProportion of cured patients in the interventional group versus the proportion of cured patients in the control group
Clinical cure will be assessed after 5-7 days from starting treatment based on: 1. Improvement in oxygenation (SpO2/FiO2 ratio). 2. Time to improvement in oxygenation. 3. Duration of hospitalization. 4. Mortality rate.
Time frame: "through study completion, an average of 3 months"
Monitoring of adverse events.
The occurrence of adverse events will be recorded on a daily basis, with a focus on: bacterial or fungal infections, elevation of AST or ALT level \> 3x the upper limit of normal range.
Time frame: "through study completion, an average of 3 months"
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.